Immune-mediated therapies are unquestionably the most exciting wave of oncologic care in decades. For the first time in the history of multiple types of cancer, to our knowledge, investigators are contemplating the label of cure for certain patients. As has been seen with other forms of noncytotoxic chemotherapies (eg, tyrosine kinase inhibitors), these drugs come with a unique set of adverse effects, many of which are neurologic in nature. Although cancer and cancer-directed therapies are not precisely within the scope of practice for most neurologists, it is imperative that neurology consultants stay abreast of this rapidly evolving field and the many neurologic complications seen therewith.
Jordan JT. Neurologic Immune-Related Adverse Events in Oncology Care. JAMA Neurol. 2016;73(8):907-908. doi:10.1001/jamaneurol.2016.1564